Portland, OR -- (SBWIRE) -- 10/04/2017 -- Metacycline is a broad spectrum semisynthetic antibiotic that belongs to tetracycline drug class. Esarondil, physiomycine, lysocline, and rotilen are some of the brand names of the antibiotic. Metacycline inhibits protein synthesis and hence cell growth by preventing the binding of aminoacyl transfer RNA to the m-RNA-ribosome complex in the ribosome 30S subunit. The antibiotic is administered in the form of oral tablets.

The wide spectrum of antimicrobial action with the use of metacyclin makes it an active component against gram-positive and gram-negative bacteria. The increase in the incidence of diseases such as rickettsiae, pneumonia, sinusitis, trench fever, and typhus increases the demand for metacycline, which in turn boosts the market growth. Nevertheless, the adverse effects associated with the use of metacycline such as hepatotoxicity, diarrhea, nausea, enterocolitis, and diarrhea hamper the market growth. In addition, the rise in the number of antibiotic resistant organisms and availability of substitutes such as miciclin, monatrex, and muvito also limit the growth of the market.

The global metacycline market is segmented based on application and geography. Based on therapeutics, it is classified into chronic bronchitis, rickettsial infections, pneumonia, trench fever, typhus, Q fever, sinusitis, and others. By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Comprehensive competitive analysis and profiles of major market players such as Merck, Boc Sciences, Manus Aktteva Biopharma LLP, Cayman Chemical, Hycultec GmbH, Abcam plc, Santa Cruz Biotechnology, Inc., Hlzel Biotech, Changzhou Pharmaceutical Factory, and The ND Pharma & Biotech Company are also provided in the report.

Metacycline Market Key Segments:

By Therapeutics

-Chronic bronchitis
-Rickettsial infections
-Pneumonia
-Trench fever
-Typhus
-Q fever
-Sinusitis
-Others